ALKS
Alkermes plcNASDAQHealthcare$34.84-0.60%ClosedMarket Cap: $5.81B
As of 2026-04-06
Valuation
P/E (TTM)
24.03
PEG
—
P/B
3.09
P/S
3.85
EV/EBITDA
13.99
DCF Value
$38.60
FCF Yield
8.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
86.3%
Operating Margin
17.2%
Net Margin
16.4%
ROE
14.5%
ROA
9.6%
ROIC
10.6%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $384.5M | 86.5% | $58.1M | $49.3M | $0.29 | — |
| FY 2025 | $1.48B | 86.3% | $254.0M | $241.7M | $1.43 | — |
| Q3 2025 | $394.2M | 86.9% | $89.1M | $82.8M | $0.49 | — |
| Q2 2025 | $390.7M | 87.3% | $93.0M | $87.1M | $0.52 | — |
| Q1 2025 | $306.5M | 83.9% | $13.8M | $22.5M | $0.13 | — |
| Q4 2024 | $430.0M | 85.6% | $162.7M | $146.5M | $0.88 | — |
| FY 2024 | $1.56B | 84.2% | $420.6M | $367.1M | $2.17 | — |
| Q3 2024 | $378.1M | 83.3% | $104.8M | $92.4M | $0.55 | — |
| Q2 2024 | $399.1M | 84.6% | $109.9M | $91.4M | $0.53 | — |
| Q1 2024 | $350.4M | 83.3% | $43.3M | $36.8M | $0.21 | — |
| Q4 2023 | $377.5M | 81.4% | $178.6M | $112.8M | $0.66 | — |
| FY 2023 | $1.66B | 84.8% | $414.1M | $355.8M | $2.10 | — |